Report cover image

Selective estrogen receptor degraders - Pipeline Insight, 2024

Publisher DelveInsight
Published Apr 01, 2024
Length 60 Pages
SKU # DEL18680078

Description

Selective estrogen receptor degraders - Pipeline Insight, 2024



DelveInsight’s, “Selective Estrogen Receptor Degraders - Pipeline Insight, 2024” report provides comprehensive insights about 14+ companies and 14+ pipeline drugs in Selective Estrogen Receptor Degraders pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
  • Global coverage
Selective Estrogen Receptor Degraders Understanding

Selective Estrogen Receptor Degraders: Overview

Estrogen receptor (ER) plays important roles in gene transcription and the proliferation of ER positive breast cancers. Selective modulation of ER has been a therapeutic target for this specific type of breast cancer.

Function - Estrogens, a class of steroid hormones, regulate the growth, development, and physiology of the human reproductive system. Estrogens also involve in the neuroendocrine, skeletal, adipogenesis, and cardiovascular systems. Estrogen signaling pathways are selectively stimulated or inhibited depending on a balance between the activities of estrogen receptor (ER) α or ERβ in target organs. ERs belong to the steroid hormone superfamily of nuclear receptors, which act as transcription factors after binding to estrogen. The gene expression regulation by ERs is to modulate biological activities, such as reproductive organ development, bone modeling, cardiovascular system functioning, metabolism, and behavior in both females and males.

Selective Estrogen Receptor Degraders- A selective estrogen receptor degrader or downregulator (SERD) is a type of drug which binds to the estrogen receptor (ER) and, in the process of doing so, causes the ER to be degraded and thus downregulated. They are used to treat estrogen receptor-sensitive or progesterone receptor-sensitive breast cancer, along with older classes of drugs like selective estrogen receptor modulators (SERMs) and aromatase inhibitors.

Selective Estrogen Receptor Degraders Emerging Drugs Chapters

This segment of the Selective Estrogen Receptor Degraders report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Selective Estrogen Receptor Degraders Emerging Drugs
  • Elacestrant: Radius Health
Elacestrant is a selective estrogen receptor degrader (SERD), out-licensed to Menarini Group, which is being evaluated for potential use as a once daily oral treatment in patients with ER+/ HER2- advanced breast cancer. Studies completed to date indicate that the compound has the potential for use as a single agent or in combination with other therapies for the treatment of breast cancer. The EMERALD Phase 3 trial is a randomized, open label, active-controlled study evaluating elacestrant as second- or third-line monotherapy in ER+/HER2- advanced/metastatic breast cancer patients.
  • Giredestrant: Genentech
Giredestrant (formerly GDC 9545) is an oral selective estrogen receptor degrader, being developed Genentech, for the treatment of breast cancer. The drug is currently in phase 3 of clinical development.

Further product details are provided in the report……..

Selective Estrogen Receptor Degraders: Therapeutic Assessment

This segment of the report provides insights about the different Selective Estrogen Receptor Degraders drugs segregated based on following parameters that define the scope of the report, such as:
  • Major Players working on Selective Estrogen Receptor Degraders
There are approx. 14+ key companies which are developing the Selective Estrogen Receptor Degraders. The companies which have their Selective Estrogen Receptor Degraders drug candidates in the most advanced stage, i.e. phase III include, Radius Health.
  • Phases
DelveInsight’s report covers around 14+ products under different phases of clinical development like
  • Late-stage products (Phase III and
  • Mid-stage products (Phase II and
  • Early-stage products (Phase I/II and Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration
Selective Estrogen Receptor Degraders pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
  • Infusion
  • Intradermal
  • Intramuscular
  • Intranasal
  • Intravaginal
  • Oral
  • Parenteral
  • Subcutaneous
  • Topical.
  • Molecule Type
Products have been categorized under various Molecule types such as
  • Vaccines
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Small molecule
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Selective Estrogen Receptor Degraders: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Selective Estrogen Receptor Degraders therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Selective Estrogen Receptor Degraders drugs.

Report Highlights
  • The companies and academics are working to assess challenges and seek opportunities that could influence Selective Estrogen Receptor Degraders R&D. The therapies under development are focused on novel approaches for Selective Estrogen Receptor Degraders.
Selective Estrogen Receptor Degraders Report Insights
  • Selective Estrogen Receptor Degraders Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs
Selective Estrogen Receptor Degraders Report Assessment
  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs
Key Questions

Current Scenario and Emerging Therapies:
  • How many companies are developing Selective Estrogen Receptor Degraders drugs?
  • How many Selective Estrogen Receptor Degraders drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for Selective Estrogen Receptor Degraders?
  • What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Selective Estrogen Receptor Degraders therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Selective Estrogen Receptor Degraders and their status?
  • What are the key designations that have been granted to the emerging drugs?
Key Players
  • Radius Health
  • Genentech
  • Olema Pharmaceuticals
  • Eli Lilly and Company
  • Aragon Pharmaceuticals
  • Novartis
  • Sanofi
  • Sun Pharma Advanced Research Company
  • G1 Therapeutics
  • Shandong Luoxin Pharmaceutical
  • AstraZeneca
  • Zeno Alpha
  • InventisBio
  • Atossa Therapeutics
  • Evestra
Key Products
  • Elacestrant
  • Giredestrant
  • OP 1250
  • LY 3484356
  • RG 6047
  • LSZ 102
  • Amcenestrant
  • SCO 120
  • Rintodestrant
  • LX 039
  • AZD 9833
  • ZN c5
  • D 0502
  • Fulvestrant intraductal
  • EC 372

Table of Contents

60 Pages
Introduction
Executive Summary
Selective Estrogen Receptor Degraders: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Selective Estrogen Receptor Degraders – DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Selective Estrogen Receptor Degraders companies’ collaborations, Licensing, Acquisition -Deal Value Trends
Selective Estrogen Receptor Degraders Collaboration Deals
Company-Company Collaborations (Licensing / Partnering) Analysis
Company-University Collaborations (Licensing / Partnering) Analysis
Late Stage Products (Phase III)
Comparative Analysis
Elacestrant: Radius Health
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
LY 3484356: Eli Lilly and Company
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
EC 372: Evestra
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Selective Estrogen Receptor Degraders Key Companies
Selective Estrogen Receptor Degraders Key Products
Selective Estrogen Receptor Degraders- Unmet Needs
Selective Estrogen Receptor Degraders- Market Drivers and Barriers
Selective Estrogen Receptor Degraders- Future Perspectives and Conclusion
Selective Estrogen Receptor Degraders Analyst Views
Selective Estrogen Receptor Degraders Key Companies
Appendix

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us